文献速递神经肿瘤

钙钛矿纳米晶探针用于胶质瘤术中IDH1突变状态快速检测

Perovskite nanocrystal probes for intraoperative in vitro pathological detection of IDH1 mutation status in glioma.
PubMed 文献 · J Neurooncol · 2025-12-08

本研究通过表面配体工程构建了溴丁酸修饰的钙钛矿纳米晶探针,用于术中肿瘤冰冻切片染色,以快速识别IDH1突变型胶质瘤。在50例胶质瘤冰冻切片中,探针可在30分钟内完成检测(孵育仅5分钟),与基因检测相比灵敏度100%、特异度84%、准确率92%(κ=0.84,P<0.001),为术中精准切除提供实时指导。

要点

  • 钙钛矿纳米晶探针经溴丁酸修饰后水氧稳定性提升,可用于术中冰冻切片荧光染色。
  • 对IDH1突变型胶质瘤检测灵敏度100%、特异度84%、准确率92%(κ=0.84,P<0.001)。
  • 探针可在30分钟内完成快速病理检测(孵育5分钟),辅助术中实时决策。

核心结论

  • 溴丁酸稳定的钙钛矿探针可实现IDH1突变型胶质瘤的快速、特异性体外检测,为术中精准切除提供实时指导。

研究设计与样本

  • 通过表面配体工程构建溴丁酸修饰的钙钛矿纳米晶探针,并用50例胶质瘤术中冰冻切片验证其对IDH1突变型胶质瘤的特异性识别能力。

主要发现

  • 50例胶质瘤冰冻切片验证显示,探针可在30分钟内完成快速病理检测(孵育5分钟)。
  • 荧光成像显示IDH1突变型胶质瘤呈特异性绿色荧光。
  • 与基因检测结果比较,探针灵敏度100%、特异度84%、阳性预测值86.2%、阴性预测值100%、准确率92%(κ=0.84,P<0.001)。

关键数值与推荐

  • 检测性能以基因检测为参照:灵敏度100%、特异度84%、阳性预测值86.2%、阴性预测值100%、准确率92%(κ=0.84,P<0.001)。
  • 检测时间:30分钟内完成,孵育时间5分钟。

临床怎么用

  • 术中可对肿瘤冰冻切片进行快速荧光染色,辅助判断IDH1突变状态,为切除策略提供实时参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to construct a perovskite quantum dot probe targeting isocitrate dehydrogenase 1 (IDH1) mutation. The probe is intended to enable rapid in vitro pathological diagnosis of IDH1-mutant glioma, guide surgeons in formulating scientific and rational resection strategies during surgery, and facilitate precise individualized intraoperative treatment for glioma patients. METHODS: Via surface ligand engineering, a perovskite nanocrystal (PNC) probe modified with bromobutyric acid (BBA) was developed in this study. This probe enhances water/oxygen stability and addresses the limitation that restricts the application of perovskite quantum dots as fluorescent probes. The probe was used to stain intraoperative tumor frozen sections to verify its specific recognition capability for IDH1-mutant glioma. RESULTS: Verification using 50 glioma frozen sections demonstrated that the probe could accomplish rapid pathological detection within 30 min (with a 5-minute incubation period). Fluorescence imaging showed specific green fluorescence in IDH1-mutant glioma. When compared with genetic testing results, the probe exhibited the following detection performance: sensitivity of 100%, specificity of 84%, positive predictive value of 86.2%, negative predictive value of 100%, and accuracy of 92% (κ = 0.84, P < 0.001). CONCLUSIONS: This BBA-stabilized perovskite probe enables rapid and specific in vitro detection of IDH1-mutant glioma. It provides real-time guidance for glioma surgery, is expected to assist surgeons in achieving precise resection of glioma, and thus advances the development of precision neuro-oncology.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Yang C, Wang H, Liu M, et al. Perovskite nanocrystal probes for intraoperative in vitro pathological detection of IDH1 mutation status in glioma. J Neurooncol. 2025. PMID: 41359079. doi:10.1007/s11060-025-05359-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。